HighTower Advisors, LLC - SANGAMO THERAPEUTICS INC ownership

SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 210 filers reported holding SANGAMO THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.0%.

Quarter-by-quarter ownership
HighTower Advisors, LLC ownership history of SANGAMO THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$255,000
-47.9%
792,313
+0.5%
0.00%
-100.0%
Q1 2024$489,000
+28.0%
788,290
-0.4%
0.00%0.0%
Q4 2023$382,000
-37.2%
791,210
-30.8%
0.00%0.0%
Q3 2023$608,000
-58.9%
1,143,140
-1.2%
0.00%
-66.7%
Q2 2023$1,479,000
-18.0%
1,156,865
+12.2%
0.00%
-25.0%
Q1 2023$1,804,000
-44.3%
1,031,132
+0.0%
0.00%
-42.9%
Q4 2022$3,236,000
-42.6%
1,030,958
-11.3%
0.01%
-53.3%
Q3 2022$5,640,000
+17.8%
1,161,925
-0.5%
0.02%
+25.0%
Q2 2022$4,789,000
-22.3%
1,167,533
+10.2%
0.01%
-14.3%
Q1 2022$6,167,000
-13.6%
1,059,517
+12.3%
0.01%
-12.5%
Q4 2021$7,138,000
+2505.1%
943,816
+3023.6%
0.02%
+1500.0%
Q3 2021$274,000
-34.9%
30,216
-14.4%
0.00%0.0%
Q2 2021$421,000
+0.7%
35,296
+5.5%
0.00%0.0%
Q1 2021$418,000
-27.7%
33,441
-9.6%
0.00%
-50.0%
Q4 2020$578,000
+57.1%
36,985
-4.5%
0.00%0.0%
Q3 2020$368,000
+1.1%
38,735
-4.9%
0.00%0.0%
Q2 2020$364,000
+29.5%
40,731
-35.7%
0.00%0.0%
Q1 2020$281,000
-13.8%
63,373
+20.5%
0.00%0.0%
Q4 2019$326,000
-33.2%
52,601
-8.6%
0.00%
-33.3%
Q3 2019$488,000
-6.7%
57,576
+18.3%
0.00%0.0%
Q2 2019$523,000
+17.5%
48,655
+4.4%
0.00%0.0%
Q1 2019$445,000
-44.7%
46,605
-34.8%
0.00%
-50.0%
Q4 2018$805,000
-48.6%
71,516
-24.2%
0.01%
-45.5%
Q3 2018$1,565,000
+358.9%
94,316
+292.1%
0.01%
+266.7%
Q2 2018$341,000
+43.9%
24,055
+93.9%
0.00%
+50.0%
Q1 2018$237,000
+17.9%
12,405
+0.8%
0.00%0.0%
Q4 2017$201,000
+1.5%
12,305
-6.1%
0.00%0.0%
Q3 2017$198,000
-23.6%
13,105
-55.4%
0.00%0.0%
Q2 2017$259,000
+25.7%
29,405
-25.4%
0.00%0.0%
Q1 2017$206,000
+71.7%
39,405
+0.3%
0.00%
+100.0%
Q4 2016$120,000
-16.7%
39,305
+26.8%
0.00%
-50.0%
Q3 2016$144,000
-19.1%
31,005
+1.3%
0.00%0.0%
Q2 2016$178,000
-7.8%
30,605
-4.7%
0.00%
+100.0%
Q1 2016$193,000
+3.2%
32,105
+56.6%
0.00%
-50.0%
Q4 2015$187,000
+70.0%
20,505
+5.1%
0.00%
+100.0%
Q3 2015$110,000
-24.1%
19,505
+48.9%
0.00%
-50.0%
Q2 2015$145,000
-6.5%
13,102
+28.5%
0.00%0.0%
Q4 2014$155,00010,2000.00%
Other shareholders
SANGAMO THERAPEUTICS INC shareholders Q2 2020
NameSharesValueWeighting ↓
Alexandria Capital, LLC 968,505$12,135,0001.23%
Golden State Equity Partners 126,608$1,586,0000.90%
McGuire Investment Group, LLC 272,801$3,418,0000.72%
Lombard Odier Asset Management (Switzerland) SA 848,429$10,631,0000.70%
Rhenman & Partners Asset Management AB 765,000$9,585,0000.67%
EMC Capital Management 72,061$903,0000.64%
WASATCH ADVISORS LP 10,328,423$129,415,0000.58%
Ceeto Capital Group, LLC 74,000$927,0000.45%
Fort Sheridan Advisors LLC 75,945$952,0000.38%
Vanguard Capital Wealth Advisors 34,580$388,679,0000.33%
View complete list of SANGAMO THERAPEUTICS INC shareholders